https://www.selleckchem.com/products/rki-1447.html
06, 95% confidence interval 2.03-4.64). In patients with glioblastoma, there was no difference in VTE incidence according to O6-methylguanine-DNA methyltransferase ( ) promoter methylation status. Patients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated, in the presence of an IDH mutation. promoter methylation in glioblastoma does not affect the incidence of VTE. Patients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated,